These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37321619)

  • 1. Use of health technology assessment in drug reimbursement decisions in China.
    Chen W; Zhang L; Hu M; Hu S
    BMJ; 2023 Jun; 381():e068915. PubMed ID: 37321619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Better defining target populations for drugs with a view to reimbursement.
    Massol J; Boissel JP
    Therapie; 2014; 69(3):235-7. PubMed ID: 24927505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework.
    Paulden M; Stafinski T; Menon D; McCabe C
    Pharmacoeconomics; 2015 Mar; 33(3):255-69. PubMed ID: 25412735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relating Health Technology Assessment recommendations and reimbursement decisions in Poland in years 2012-2014, a retrospective analysis.
    Kawalec P; Malinowski KP
    Health Policy; 2016 Nov; 120(11):1240-1248. PubMed ID: 28029415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pitfalls in reimbursement decisions for oncology drugs in South Korea: need for addressing the ethical dimensions in technology assessment.
    Cho E; Park EC; Kang MS
    Asian Pac J Cancer Prev; 2013; 14(6):3785-92. PubMed ID: 23886183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends and determinants in reimbursement decision-making in Poland in the years 2013-2015.
    Kawalec P; Malinowski KP; Trąbka W
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):197-205. PubMed ID: 28952400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harmonization of evidence requirements for health technology assessment in reimbursement decision making.
    Hutton J; Trueman P; Facey K
    Int J Technol Assess Health Care; 2008; 24(4):511-7. PubMed ID: 18828948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
    Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
    Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy.
    Chen Y; Dong H; Wei Y; Yang Y; Ming J; Yu H
    BMJ; 2023 Jun; 381():e069963. PubMed ID: 37321628
    [No Abstract]   [Full Text] [Related]  

  • 10. Reimbursement of biosimilars in Poland: is there a link to health technology assessment?
    Neumann D; Jabłecka A
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):781-792. PubMed ID: 26768654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
    Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
    J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do Profit Margins of Pharmaceuticals Influence Reimbursement Decisions? A Discrete Choice Experiment Among Dutch Healthcare Decision Makers.
    Enzing JJ; Himmler S; Knies S; Brouwer WBF
    Value Health; 2022 Feb; 25(2):222-229. PubMed ID: 35094795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eight-year experience of using HTA in drug reimbursement: South Korea.
    Bae EY; Hong JM; Kwon HY; Jang S; Lee HJ; Bae S; Yang BM
    Health Policy; 2016 Jun; 120(6):612-20. PubMed ID: 27086557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions-Report of the ISPOR Stated Preference Research Special Interest Group.
    Marsh K; van Til JA; Molsen-David E; Juhnke C; Hawken N; Oehrlein EM; Choi YC; Duenas A; Greiner W; Haas K; Hiligsmann M; Hockley KS; Ivlev I; Liu F; Ostermann J; Poder T; Poon JL; Muehlbacher A
    Value Health; 2020 Jul; 23(7):831-841. PubMed ID: 32762984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health Technology Assessment and Health Care Reimbursement in the European Union: Permissive Dissensus and the Limits of Harmonization through the Backdoor.
    Löblová O
    J Health Polit Policy Law; 2021 Feb; 46(1):117-145. PubMed ID: 33085959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.
    Pauwels K; Huys I; De Nys K; Casteels M; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):859-68. PubMed ID: 25978862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of health technology assessment reports on decision making in Austria.
    Zechmeister I; Schumacher I
    Int J Technol Assess Health Care; 2012 Jan; 28(1):77-84. PubMed ID: 22233544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence-based decision-making and health technology assessment in South Korea.
    Park SH; Lee SM
    Value Health; 2008 Mar; 11 Suppl 1():S163-4. PubMed ID: 18387062
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluating options for decision making on costly hospital drugs in Austria.
    Wolf S; Zechmeister-Koss I; Grössmann N; Wild C
    Int J Technol Assess Health Care; 2020 Jun; 36(3):277-284. PubMed ID: 32404223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.